Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 12, 2007. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event rather than comprehensive financial performance.
Material Changes
The material change reported is an increase in the Ordinary share holdings of two individuals resulting from the reinvestment of dividends paid on October 11, 2007, under a Single Company ISA. The transaction details are as follows:
- Mr J S Heslop: Acquired 5 Ordinary shares.
- Mr A P Witty: Acquired 4 Ordinary shares.
- Transaction Price: GBP 13.07 per Ordinary share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares held by Mr J S Heslop and Mr A P Witty post-transaction to assess their total exposure.
- Confirm the dividend reinvestment plan terms and the specific price of GBP 13.07 per share on October 11, 2007.
- Note that this filing does not contain financial results; investors should refer to the company's Form 20-F or interim reports for financial data.